News About <![CDATA[SUNESIS PHARMA]]> News About en-us <![CDATA[Mid-Morning Market Update: Markets Drop; Family Dollar Plans To Close 370 Stores]]> Following the market opening Thursday, the Dow traded down 0.07 percent to 16,426.40 while the NASDAQ tumbled 0.82 percent to ...

]]>
<![CDATA[Roth Boosts PT on Sunesis Pharma (SNSS) to $15; Focus Remains on Vosaroxin]]> <![CDATA[Sunesis Announces Presentation of Positive Results From Ongoing MD Anderson-Sponsored Trial of Vosaroxin in AML and High-Risk MDS]]> <![CDATA[Sunesis Announces MD Anderson Sponsored Trial of Vosaroxin in AML and High-Risk MDS Poster to be Presented at AACR 2014]]> <![CDATA[Appointments, Financial Reports, and FDA Approvals - Analyst Notes on Hospira, Karyopharm, Revance, Pluristem, and Sunesis]]> <![CDATA[Sunesis Pharmaceuticals (SNSS) Lost 15c/Share in Q4]]> <![CDATA[Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2013 Financial Results and Recent Highlights]]> <![CDATA[Trading Radar for 03/06: Ciena (CIEN), Kroger (KR), Staples (SPLS), Quiksilver (QIHU), Violin Memory (VMEM) Report]]> <![CDATA[Watch And Wait Wednesday – Show Us 10,500!]]> <![CDATA[Look At This Stock - SNSS]]> <![CDATA[Sunesis to Present at Upcoming Investor Conferences]]> <![CDATA[Sunesis to Host Conference Call on March 6th to Discuss Fourth Quarter and Full-Year 2013 Financial Results and Recent Highlights]]> <![CDATA[Pre-Open Stock Movers 2/27: (JCP) (PEIX) (BBY) Higher; (INO) (DAR) (CHS) Lower (more...)]]> <![CDATA[Sunesis Pharma (SNSS) Prices $43M Common Stock + Warrants Offering]]> <![CDATA[Sunesis Announces Pricing of a $43.0 Million Public Offering of Common Stock and Warrants]]> <![CDATA[After Hours Stock Movers 2/26: (JCP) (BIDU) (TSLA) Higher; (HK) (INO) (NDLS) Lower (more...)]]> <![CDATA[Sunesis Pharmaceuticals (SNSS) Plans Common, Warrants Offering]]> <![CDATA[Sunesis Announces Proposed Public Offering of Common Stock and Warrants]]> <![CDATA[Lower Close As Consumer Confidence Drops]]> <![CDATA[Tuesday Sector Leaders: Biotechnology, Apparel Stores]]> <![CDATA[Catalysts Drive These Stocks]]> Related posts:
  1. Can Biotech Repeat In 2014? [Gilead Sciences, Inc., Biogen Idec Inc, Celgene Corporation]
  2. Intercept Pharmaceuticals Inc (ICPT) Pushes SPDR Biotech ETF Ahead Of Rivals
  3. The Stocks To Own Right Now [Caterpillar Inc., eBay Inc, 3M Co, United Technologies Corporation]
  4. Stocks For Speculative Investors [3D Systems Corporation, Stratasys, Ltd.]
  5. How To Profit From The Dow’s “Dogs” [AT&T Inc., Wal-Mart Stores, Inc., McDonald's Corporation, Chevron Corporation]
]]>
<![CDATA[7 Biotechnology Stocks to Sell Now]]> The ratings of seven biotechnology stocks are down this week, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

The post 7 Biotechnology Stocks to Sell Now appeared first on InvestorPlace.

]]>
<![CDATA[7 Biotechnology Stocks to Sell Now]]> ]]> <![CDATA[October 18th Options Now Available For Sunesis Pharmaceuticals Inc (SNSS)]]> <![CDATA[October 18th Options Now Available For Sunesis Pharmaceuticals Inc (SNSS)]]> <![CDATA[Maxim Integrated Products, Inc. (NASDAQ:MXIM) and Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Added to Equity Profile Report's NASDAQ Active Stock Watch List.]]> Wilmington, DE -- (SBWIRE) -- 02/10/2014 -- Equity Profile Report expands its NASDAQ Active Stock Weekly Watch List adding Maxim Integrated Products, Inc. (NASDAQ:MXIM) and Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS).

]]>
<![CDATA[NASDAQ Gainers Watch List: Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) and Celldex Therapeutics, Inc. (NASDAQ:CLDX) Added to Growing Stock Report's NASDAQ Gainers Watch List.]]> New York, NY -- (SBWIRE) -- 02/10/2014 -- Growing Stock Report expands its NASDAQ Gainers Weekly Watch List adding Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) and Celldex Therapeutics, Inc. (NASDAQ:CLDX).

]]>
<![CDATA[Sunesis Appoints Joseph I. DePinto as Chief Commercial Officer, Updates VALOR Timeline to Unblinding of Data]]> <![CDATA[Friday Sector Leaders: Biotechnology, Drugs]]> <![CDATA[Pre-Open Stock Movers 2/7: (IMN) (LQDT) (EXPE) Higher; (FWM) (ELON) (LNKD) Lower (more...)]]> <![CDATA[Sunesis to Present at Upcoming Investor Conferences]]> <![CDATA[7 Biotechnology Stocks to Sell Now]]> This week, the overall grades of seven biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

The post 7 Biotechnology Stocks to Sell Now appeared first on InvestorPlace.

]]>
<![CDATA[7 Biotechnology Stocks to Sell Now]]> ]]> <![CDATA[Notable Movers - Array Biopharma Inc (NASDAQ:ARRY), BIOLASE Inc (NASDAQ:BIOL), Sunesis Pharmaceuticals, Inc (NASDAQ:SNSS), Triangle Petroleum Corporation (NYSEMKT:TPLM)]]> New York, NY -- (SBWIRE) -- 01/13/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Array Biopharma Inc (NASDAQ:ARRY), BIOLASE Inc (NASDAQ:BIOL), Sunesis Pharmaceuticals, Inc (NASDAQ:SNSS), Triangle Petroleum Corporation (NYSEMKT:TPLM)

]]>
<![CDATA[Notable Movers- Gevo, Inc. (NASDAQ:GEVO), Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP), BIOLASE Inc (NASDAQ:BIOL), Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS)]]> New YorK, NY -- (SBWIRE) -- 01/11/2014 -- To receive alerts before the crowd, please take 7 seconds to sign up for our Premium SMS Alerts. Grab your cell phone and text the word "PICKS" to "555888”.

]]>
<![CDATA[Roth Capital Keeps Sunesis Pharma (SNSS) at Buy; Hematology Expansion Positive, Eyes Still on VALOR]]> <![CDATA[Sunesis Pharmaceuticals (SNSS) Licenses Two Kinase Inhibitor Programs (BIIB)]]> <![CDATA[Sunesis Pharmaceuticals Announces Global Licenses for Two Kinase Inhibitor Programs]]> Sunesis Pharmaceuticals (Nasdaq: SNSS) today announced that it has expanded its hematology franchise through separate global licensing agreements for two preclinical kinase inhibitor programs. The first agreement, with Biogen Idec (Nasdaq: BIIB), is for global commercial rights to SNS-062, a potent and selective non-covalently binding oral

]]>
<![CDATA[Sunesis Pharmaceuticals Expands Hematology Franchise With Global Licenses to Two Kinase Inhibitor Programs]]> <![CDATA[Sunesis Pharma (SNSS) Initiates Vosaroxin + Azacitidine as MDS Treatment]]> <![CDATA[Sunesis Pharmaceuticals Announces Initiation of an Investigator-Sponsored Trial Evaluating Vosaroxin in Combination With Azacitidine in MDS]]> <![CDATA[Sunesis Pharmaceuticals to Present at the Piper Jaffray 25th Annual Healthcare Conference]]> <![CDATA[Sunesis Pharmaceuticals (SNSS) Tops Q3 EPS by 4c]]> <![CDATA[Sunesis Pharmaceuticals Reports Third Quarter Financial Results and Recent Highlights]]> <![CDATA[Trading Radar for 11/12: DISH Network (DISH), Potbelly (PBPB), Dick's (DKS), Yingli Green Energy (YGE) Report]]> <![CDATA[Sunesis to Present at the 2013 Credit Suisse Annual Health Care Conference]]> <![CDATA[Sunesis to Host Conference Call on November 12th to Discuss Third Quarter Financial Results and Recent Highlights]]> <![CDATA[Sunesis Pharmaceuticals Announces Initiation of Phase 2 Cohort of MD Anderson Sponsored Study of Vosaroxin in AML and High-Risk MDS]]> <![CDATA[Sunesis Pharmaceuticals Announces Investigator-Sponsored Phase I/II Trial Evaluating Vosaroxin in Myelodysplastic Syndrome]]> Sunesis Pharmaceuticals (NASDAQ: SNSS) today announced the initiation of a Phase I/II investigator-sponsored trial of vosaroxin, the company's lead product candidate, in adult patients with previously treated intermediate-2 or high-risk myelodysplastic syndrome (MDS). The trial is being conducted at Weill Cornell Medical College and New York-Presbyterian Hospital under

]]>
<![CDATA[Sunesis Pharmaceuticals Announces Initiation of an Investigator-Sponsored Phase I/II Trial Evaluating Vosaroxin in Myelodysplastic Syndrome]]>